<DOC>
	<DOCNO>NCT00230854</DOCNO>
	<brief_summary>The purpose study assess safety efficacy repeat intravenous infusion EMZ702 combination pegylated interferon ribavirin patient chronic hepatitis C genotype 1 .</brief_summary>
	<brief_title>Study Non-responder Hepatitis C Genotype 1 Patients With EMZ702 , Pegylated Interferon Ribavirin</brief_title>
	<detailed_description>In study , 28 patient chronic hepatitis C genotype 1 fail previous treatment pegylated interferon plus ribavirin treat . The study treatment consist type dos pegylated interferon ribavirin patient fail respond plus EMZ702 . EMZ702 administer intravenously twice week first 12 week treatment . Thereafter accord viral response , patient continue receive pegylated interferon ribavirin 36 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Hepatitis , Viral , Human</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Hepatitis C virus ( HCV ) genotype 1 Previous therapy pegylated interferon ribavirin Documented previous treatment failure Hepatic dysfunction Coinfection hepatitis B HIV Other unrelated liver diseases Liver cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>hepatitis C</keyword>
	<keyword>genotype 1</keyword>
	<keyword>non-responders</keyword>
	<keyword>viral hepatitis</keyword>
</DOC>